Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Inclusion Criteria: * signed informed consent prior to initiation of any study-specific procedures and treatment * documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-002 * Investigator considers patient has been tolerating treatment on study CMD-2019-001 and may benefit from continued treatment with CuATSM Exclusion Criteria: * not dependent on mechanical ventilation